Opendata, web and dolomites

STRATIFY SIGNED

Diagnostic autoantibody assay to stratify bone marrow failure diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRATIFY project word cloud

Explore the words cloud of the STRATIFY project. It provides you a very rough idea of what is the project "STRATIFY" about.

subset    lies    vast    difficulties    stem    proper    producing    autoantibody    acquired    life    leukopenia    pharma    haematological    personalised    diagnosis    misdiagnosis    simultaneous    therapy    commercialisation    exclusion    options    suggesting    protein    discovery    reagent    threatening    aa    validity    destroyed    diseases    aplastic    machines    inherently    carry    cog    laboratory    reveal    innovation    anaemia    pathogenesis    lack    tests    white    confirming    background    savings    defective    bmfs    genetic    thousands    time    believe    poc    pathology    healthcare    therapies    manifest    diagnostic    positivity    bone    accuracy    screening    introducing    actions    inexpensive    blood    marrow    inappropriate    takes    group    heterogenous    serious    companies    lives    red    unexplained    companion    potentially    clinical    patients    clinicians    elderly    syndromes    made    underlying    rare    constitute    erc    kit    preliminary    cells    hundreds    follows    serology    samples   

Project "STRATIFY" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 150˙000.00

Map

 Project objective

Bone marrow failure syndromes (BMFS) such as aplastic anaemia (AA) are a heterogenous group of rare diseases that manifest as loss of red and white blood cells. In these potentially life-threatening diseases, blood producing stem cells may be inherently defective or become destroyed due to acquired cause. Diagnostic difficulties of BMFS constitute a significant clinical problem as the diagnosis takes long, and misdiagnosis may lead to inappropriate management with serious side effects.

In our ERC-CoG project we made an exciting discovery and identified a novel autoantibody in AA patients’ blood samples. Autoantibody positivity defined a distinct group of patients with similar genetic background suggesting common pathogenesis. Our preliminary results show that the autoantibody analysis has great potential to reveal cases of AA and define a subset of other BMFS patients with similar underlying pathology that currently lack proper diagnosis. Furthermore, vast commercialisation potential lies in introducing it as an exclusion laboratory test in patients with unexplained anaemia or leukopenia (common problems in elderly). The improved diagnostic accuracy and the targeted personalised therapy that follows has the potential to impact the lives of hundreds of thousands of patients over time and bring simultaneous healthcare savings. Further, understanding of the role of target protein of the autoantibody in bone marrow failure may lead to targeted therapies in the future.

We believe that the test can be developed as an inexpensive reagent kit to be used in serology machines for autoantibody screening. In order to improve the commercialisation potential, we will carry out 1) Technology PoC for confirming the approach validity, and 2) Pre-commercialisation actions for evaluating the best commercialisation options for bringing the innovation to clinicians managing haematological patients and for pharma companies as companion diagnostic tests together with their therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRATIFY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRATIFY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

THERMONANO (2018)

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Read More  

EXTREME (2020)

The Epistemology and Ethics of Fundamentalism

Read More